Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy

Kidney International

Volumn 68, Issue 6, 2005, Pages 2593-2598

  Hartmann, Bertram ^b   Schmid, Gerald ^b   Graeb, Christian ^b   Bruns, Christiane J ^b   Fischereder, Michael ^b   Jauch, Karl Walter ^b   Heeschen, Christopher ^b   Guba, Markus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Rapamycin; Sirolimus; Tailored immunosuppression

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; S6 KINASE; THREONINE;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; ENZYME PHOSPHORYLATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 32844467779     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00731.x     Document Type: Article

References (10)

1. KREIS H, OBERBAUER R, CAMPISTOL JM, et al: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15:809-817, 2004
2. SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335-340, 1998
3. FISCHEREDER M, KRETZLER M: New immunosuppressive strategies in renal transplant recipients. J Nephrol 17:9-18, 2004
4. DUFNER A, THOMAS G: Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253:100-109, 1999
5. BOULAY A, ZUMSTEIN-MECKER S, STEPHAN C, et al: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261, 2004
6. GALLANT HL, YATSCOFF RW: P70 S6 kinase assay: A pharmacodynamic monitoring strategy for rapamycin; assay development. Transplant Proc 28:3058-3061, 1996
7. PERALBA JM, DEGRAFFENRIED L, FRIEDRICHS W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003
8. SEELIGER H, GUBA M, KOEHL GE, et al: Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10:1843-1852, 2004
9. KAHAN BD: Sirolimus: A ten-year perspective. Transplant Proc 36:71-75, 2004
10. VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, et al: A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 75:1934-1939, 2003